The JAK2(V617F) mutation and the role of therapeutic agents in alleviating myeloproliferative neoplasm symptom burden

Alleviating symptom burden in patients with myeloproliferative neoplasms (MPNs) is imperative to achieving optimal management. Research remains to elucidate the relationship between the JAK2(V617F) (Janus kinase 2) mutation present in many MPN patients, and the symptomatology they experience. This r...

Descripción completa

Detalles Bibliográficos
Autores principales: Orbell, Lai Yee, Abutheraa, Nouf, Duncombe, Andrew S, McMullin, Mary Frances, Mesa, Ruben, McShane, Charlene M, James, Glen, Anderson, Lesley A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Haematologic Malignancy ‐ Myeloid
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10660120/
https://www.ncbi.nlm.nih.gov/pubmed/38024634
http://dx.doi.org/10.1002/jha2.805

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10660120/
https://www.ncbi.nlm.nih.gov/pubmed/38024634
http://dx.doi.org/10.1002/jha2.805

Ejemplares similares